Pharmacology

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacology Pharmacology GENERAL CONCEPTS OF PHARMACOLOGY 1. Absorption: The movement of the drug from the site of administration into the blood. ✽ No medication has a single action; all medications a. Drug absorption can be altered by the have the potential to alter more that one body function. increase or decrease in gastric emptying, by For example, aspirin may be given for anti-inflammatory changing the gastric pH, or by forming drug action for arthritis, or for antiplatelet action to prevent complexes. strokes. b. Administration affects absorption, for example subcutaneous injection vs oral ✔ NURSING PRIORITY: Many medications have administration. several actions that are desirable. Carefully evaluate 2. Distribution: The movement of the drug through the question to determine the desired response of the the body. Drug metabolism and excretion as well as medication for the specific client situation. cardiac output will affect the distribution of a drug. 3. Metabolism: the alteration of the drug structure, the alterations occur in the liver with excretion by the A. Desired action: the desired, predictable response for kidney. which the medication is administered. 4. Excretion: Changes in liver and renal function as B. Side effects (drug reaction): the undesirable or unwant- well as changes in cardiac output will affect the ed response; frequently predictable. excretion of a drug. C. Unpredictable response: the unusual response to a medi cation. ✔ OLDER ADULT PRIORITY: Creatinine clearance 1. Idiosyncratic reaction: an individual, unexpected re is a more effective indication of renal function that serum sponse to a medication. creatinine in older adults. 2. Allergic reaction: may or may not occur with the initial dose of medication; occurs with subsequent F. Potential for Abuse: Controlled Substances Act, doses because it requires that the immune system 1970, defines rules for the manufacture and respond with the production of antibodies in order distribution of drugs that are considered to have a to trigger the allergic reaction. potential for abuse. D. The Drug Amendments of 1962 made it mandatory that 1. 5 Categories of medications: Schedules I, II, III, each medication have one official name. IV, V—potential for abuse decreases with each 1. Generic name (nonproprietary): the official category, medications in Schedule V have lowest designated name that the medication is listed under potential for abuse. in official publications. 2. Schedule I drugs are highly addictive 2. Chemical name: designates the specific chemical (e.g., heroin) and are not used in therapeutic composition of the medication. administration of medications, Schedule V 3. Trade name (proprietary name, brand name): the drugs (e.g., diphenoxylate hydrochloride name designated and registered by a specific [Lomotil]) have the lowest potential for abuse. manufacturer. Drug Actions TEST ALERT: Typically, the medications on the NCLEX-PN examination will be identified with A. Desired action: the desired, predictable response for both the generic and trade name—for example: which the medication is administered. diazepam (Valium). B. Adverse drug reactions (ADR): an undesirable drug effect, ranging from mild untoward effects to severe responses. E. Pharmacokinetic process: Consists of four phases - absorption, distribution, metabolism, or excretion, acting together to determine the concentration of a drug at its site of action. 69 70 CHAPTER 4 Pharmacology E. Drug incompatibility: a chemical or physical reaction ✔ OLDER ADULT PRIORITY: ADRs are 7 times that occurs when two or more drugs are combined in more common in older adults than in young adults. vitro (outside the body). F. Breast-feeding: advise women who are lactating to 1. Side effects: undesirable drug effects, ranging from always advise their health care provider; medications mild untoward effects to severe responses that occur may be excreted in breast milk. at normal drug dosages. 2. Toxicity: drug reactions that primarily occur as a TEST ALERT: Use critical thinking skills when result of receiving an excessive dose (e.g., medica- considering the effects and/or outcomes of medica- tion error, poisoning); can also include severe reac- tions; identify any contraindications to administration tions (anaphylaxis) that occur regardless of the dose. of a prescribed or OTC medication. 3. Allergic reactions: drug reaction that occurs as a re- sult of prior sensitization and results in an immune G. Food and Drug Administration pregnancy risk categories response. Intensity can range from very mild to very (Table 4-1). severe (anaphylaxis). 4. Idiosyncratic effect: an uncommon drug response. Herbal Supplements C. Tolerance: an increased dose is required to maintain ex- A. Use of herbs to treat health problems is the most pected drug response. For example, when a client with common form of alternative medicine, which can be chronic pain may requires higher doses of an analgesic defined as treatment practices that are not widely to achieve pain relief. accepted or practiced by mainstream clinicians in a D. Dependence: an expected response to repeated use of a given culture. drug, resulting in physical signs and symptoms of with- B. The word natural is not synonymous with safe! drawal when the serum drug level decreases suddenly. Remember, poison ivy and tobacco are natural, too. For example, when a client abruptly stops taking a strong C. Some commonly used medicinal herbs (Table 4-2). opioid agonist (methadone) and develops symptoms of withdrawal. E. Addiction: the continued use of a psychoactive sub- ✔ NURSING PRIORITY: Unlike conventional stance regardless of physical, psychologic, or social drugs, herbal and other dietary supplements can be mar- harm. keted without any proof of safety or efficacy. Dietary sup- plements are not regulated by the FDA. Drug Interactions A. An altered or modified action or effect of a drug as a re- sult of interaction with one or more drugs. It is not an MEDICATION ADMINISTRATION adverse drug reaction or drug toxicity. B. Drug incompatibility: a chemical or physical reaction that occurs between two or more drugs outside the body. ✔ NURSING PRIORITY: The nurse’s responsibil- ity in administering medication is influenced by three primary factors: nursing guidelines for safe medication TEST ALERT: Assess client for actual or potential administration, pharmacological implications of the side effects and adverse effects of medications; medication, and the legal aspects of medication adminis- identify symptoms/evidence of allergic reactions to tration. medications; implement procedures to counteract adverse effects of medications; evaluate and document Nursing Responsibilities in Medication client response to actions taken to counteract side effects and adverse effects of medications. Administration A. Follow the “7 Rights” of medication administration. C. Potentiation effect (synergistic effect): if two or more 1. Right medication. drugs are given together and this increases the 2. Right dosage. therapeutic effects, it is beneficial; if it increases adverse 3. Right route of administration. effects, it may be detrimental. For example, a diuretic 4. Right time. and a beta blocker may be give together for hypertension. 5. Right client. D. Antagonistic or inhibitory effect: if two or more drugs 6. Right charting (documentation). are given together, one may inhibit the effect of the 7. Right technique other; this may be beneficial or detrimental. For example, naloxone (Narcan) may be given to suppress the effects of morphine. TEST ALERT: Administer medications according to the “7 Rights” of medication administration. CHAPTER 4 Phamacology 71 Table 4-1 FOOD AND DRUG ADMINISTRATION PREGNANCY RISK CATEGORIES Category Description A Remote Risk of Fetal Harm: Adequate and well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities. B Slightly More Risk Than A: Animal studies have revealed no evidence of harm to the fetus; however, there are no adequate and well-controlled studies in pregnant women. or Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus. C Greater Risk Than B: Animal studies have shown an adverse effect, and there are no adequate and well- controlled studies in pregnant women. No animal studies have been conducted, and there are no adequate and well-controlled studies in pregnant women. D Proven Risk of Fetal Harm: Studies—adequate well-controlled or observational—in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. X Proven Risk of Fetal Harm: Studies—adequate well-controlled or observational—in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. The use of the product is contrain dicated in women who are or may become pregnant. Modified from Lehne RA: Pharmacology for nursing care, ed 6, St. Louis, 2007, Saunders; and Meadows M: Pregnancy and drug dilemma, FDA Consumer Magazine, May-June 2001. Available at www.fda.gov/fdac/features/2001/301_preg.html. Table 4-2 COMMONLY USED MEDICINAL HERBS Medicinal Herb Drug Interactions • Black cohosh is a popular treatment for acute symptoms of meno- May potentiate hypotensive effects of antihypertensive drugs, pause and premenstrual syndrome (PMS). Minor side effect of as well as hypoglycemic action of insulin and oral upset stomach may occur. hypoglycemics. • Feverfew for treatment of migraine, fever; stimulates
Recommended publications
  • Unit 4: Medication Administration Fundamental of Nursing
    Unit 4: Medication Administration Fundamental of Nursing Unit 4: Medication Administration: Medication: Is a substance administered for the diagnosis, cure, treatment, relief, or prevention of disease. Six Rights of Medication Administration After paramedics have received the medication or fluid order, they should then administer the drug in question. In performing drug administration, pre-hospital care providers adhere to the six rights of medication administration: 1. Right patient 2. Right medication 3. Right dose 4. Right route 5. Right time 6. Right documentation Basic principle of nurse on drugs administration 1. The nurse must know the drug's prescribed dose, method of administration, actions, expected therapeutic effect, possible interactions with other drugs, and adverse effects. 2. The nurse must know the institution's administration procedures for the client's welfare and the nurse's legal protection. 3. The nurse must Review physician's order for completeness the client's name, date of the order, name of the drug, dose, rout, time of administration, and the physician's signature. 1 Unit 4: Medication Administration Fundamental of Nursing 4. The nurse discusses the medication and its actions with the client; recheck the medication order if the client disagrees with the dose or the physician's order. 5. The nurse must check the physician's order against the client's medication administration record for accuracy. 6. The nurse gives the patient the right to know about the medication he is receiving and the right to refuse it. Routes of Administration A: Enteral Tract Routes The common enteral routes of administration used in general medical practice are as follows: 1.
    [Show full text]
  • Preparation of the Materials for an Injection ĂŢ
    PREPARATION OF THE MATERIALS FOR AN INJECTION Ovidiu Fabian, Emilia ăţ Learning objectives What you should know What is an injection What are the parenteral routes of administration of drugs; what types of injections are there What are the advantages of parenteral drug administration What is a syringe; which are the parts of the syringe and needle What information should be looked for in the prescription / medical indication What important information should be looked for on the syringe package What information should be sought on the package of the medicine to be administered What materials are necessary for the injection procedure The technique of dissolving medication and aspirating it into the syringe What is a container for sharp objects What you should do Choose the right materials for an injection Check the identity of the patient that is about to have the injection Check the ’medication Open the packaging for the syringe / needle Attach the needle to the syringe; loosen and remove the needle sheath Open a vial and aspire the contents into the syringe Dissolve a medicinal powder in the vial and absorb the contents into the syringe Place the filled syringe into a position that is convenient to use Disinfect the place of the future injection Keep material sterility throughout the entire procedure Discharge the needle into the container for sharp objects Definition Injection is a procedure by which a drug substance is introduced into tissues using a special needle and a syringe. Drug administration through injections
    [Show full text]
  • Smallpox Vaccination by Intradermal Jet Injection* 1
    Bull. Org. mond. San)e 1969, 41, 749-760 Bull. Wld Hlth Org. Smallpox Vaccination by Intradermal Jet Injection* 1. Introduction, Background and Results of Pilot Studies J. DONALD MILLAR,1 RONALD R. ROBERTO,2 HERTA WULFF,3 HERBERT A. WENNER4 & D. A. HENDERSON 5 Jet injection has met with great success in the rapid and effective mass administration of several immunizing agents. The recent development of a jet injector nozzle specifically designedfor intradermal inoculation suggested thepossible extension ofjet injector methodo- logy to mass smallpox vaccination. A total of 156 volunteer subjects, 16 unvaccinated and 140 vaccinated more than 5 years previously, received either undiluted smallpox vaccine by the multiple-pressure technique, or 0.1 ml of various dilutions of smallpox vaccine by jet injector using the new nozzle. Cutaneous and serological responses in revaccinees revealed that jet injection of diluted vaccine with a titre of 107 TCID50/ml was as effective as multiple-pressure inoculation of undiluted vaccine. Among the small number ofprimary vaccinees, jet injection ofdiluted vaccine with a titre of 106 TCID5o/ml appearedas effective as multiple-pressure inoculation of undiluted vaccine. No complications of vaccination occurred. The findings confirm the utility of the intradermal nozzle for jet injection of smallpox vaccine. In view of the speed ofadministration and the economy of vaccine, it is suggested that there is a distinct role for jet injection in global smallpox eradication efforts. Further studies on larger numbers of unvaccinated subjects and on persons with significant residual vaccinial immunity are needed to define the optimal concentration of vaccine for mass vaccination by iet injection.
    [Show full text]
  • Injections in Dogs and Cats
    SOP: Injections in Dogs and Cats These SOPs were developed by the Office of the University Veterinarian and reviewed by Virginia Tech IACUC to provide a reference and guidance to investigators during protocol preparation and IACUC reviewers during protocol review. They can be used as referenced descriptions for procedures on IACUC protocols. However, it is the sole responsibility of the Principal Investigator to ensure that the referenced SOPs adequately cover and accurately represent procedures to be undertaken in any research project. Any modification to procedure as described in the SOP must be outlined in each IACUC protocol application (e.g. if the Principal Investigator plans to use a needle size that is not referenced in the SOP, simply state that alteration in the IACUC protocol itself). Table of Contents I. Procedure Summary & Goal ......................................................................................... 1 II. Personal Protective Equipment & Hygiene ................................................................... 1 III. Supply List .................................................................................................................... 1 IV. Detailed Procedure ........................................................................................................ 1 V. Potential Adverse Effects, Mitigation, or Treatment .................................................... 2 VI. Variations .....................................................................................................................
    [Show full text]
  • Intradermal Therapy (Mesotherapy) in Derma- Tology
    Canzona F, Mammucari M, Tuzi A, Maggiori E, Grosso MG, Antonaci L, Santini S, Catizzone AR, Troili F, Gallo A, Paolucci T, Rocchi P, Guglielmo C, Russo D, Giorgio C, Dorato D, Marzo RD, Viglione G, Fiorentini AG, Giardini M, Natoli S. Intradermal Therapy (mesotherapy) in Derma- tology. J Dermatol & Skin Sci. 2020;2(1):22-25 Mini-Review Article Open Access Intradermal Therapy (mesotherapy) in Dermatology Flora Canzona1, Mammucari Massimo2*, Arianna Tuzi3, Enrica Maggiori2, Maria Gabriella Grosso4, Luciano Antonaci2, Stefania Santini3, Anna Rosa Catizzone3, Fiammetta Troili3, Alessandra Gallo3, Teresa Paolucci3, Piergiovanni Rocchi3, Costanza Guglielmo3, Domenico Russo5, Chiara Giorgio6, Dario Dorato3, Raffaele Di Marzo3, Giovanna Viglione3, Anna G Fiorentini3, Manuela Giardini3, Silvia Natoli7. 1Istituto Dermopatico dell’Immacolata, IRCCS Foundation, Rome, Italy 2Primary Care Unit ASL RM 1, Rome, Italy 3Member of the Italian Society of Mesotherapy, Rome, Italy 4Ospedale Israelitico, Rome Italy 5San Marco Hospice and Palliative Care, Latina, Italy 6Rehabilitation Unit, F Pirinei Hospital, Altamura (BA), Italy 7Department of Clinical Science and Translational Medicine, Tor Vergata University, Rome, Italy Article Info Abstract Article Notes Mesotherapy consists of a series of micro injections in the superficial layer Received: January 28, 2020 of the skin of active ingredients that slowly diffuse into the underlying tissues. Accepted: March 17, 2020 This technique is applied in different clinical conditions and also in dermatology *Correspondence: it could play a useful role in the treatment path of many patients. However, *Dr.Mammucari Massimo, Primary Care Unit ASL RM 1, Rome, further clinical studies are needed to standardize its application in various Italy; Email: [email protected].
    [Show full text]
  • Intradermal Injection Simulator LF01008U Instruction Manual
    Other Available Simulators LF00698U Adult Injectable Arm (Light) LF01162U Venatech IV Trainer LF00958U Pediatric Injectable Arm LF01184U Venatech IM & Sub Q LF00961U Intramuscular Injection LF00995U Arterial Puncture Arm LF01184U LF00999U Pediatric Injectable Head LF01005U First Aid Arm Intradermal Injection LF01037U Hemodialysis Practice Arm LF01121U Advanced IV Arm Simulator LF01131U Venipuncture and Injection Arm LF01139U Advanced IV Hand LF01008U Instruction Manual LF00961U LF01121U Fort Atkinson 901 Janesville Avenue, P.O. Box 901 Fort Atkinson, Wisconsin 53538-0901 1.800.558.9595 Products by Nasco eNasco.com • E-mail: [email protected] COPYRIGHT © NASCO 1982 PRINTED IN U.S.A. NP 53-82/RV 6-15 Other Available Simulators LF00698U Adult Injectable Arm (Light) LF01162U Venatech IV Trainer LF00958U Pediatric Injectable Arm LF01184U Venatech IM & Sub Q LF00961U Intramuscular Injection LF00995U Arterial Puncture Arm LF01184U LF00999U Pediatric Injectable Head LF01005U First Aid Arm Intradermal Injection LF01037U Hemodialysis Practice Arm LF01121U Advanced IV Arm Simulator LF01131U Venipuncture and Injection Arm LF01139U Advanced IV Hand LF01008U Instruction Manual LF00961U LF01121U Fort Atkinson 901 Janesville Avenue, P.O. Box 901 Fort Atkinson, Wisconsin 53538-0901 1.800.558.9595 Products by Nasco eNasco.com • E-mail: [email protected] COPYRIGHT © NASCO 1982 PRINTED IN U.S.A. NP 53-82/RV 6-15 NP053_82.indd 1 6/1/15 3:18 PM A. Care of the Intradermal Sites Puncturing the skin with needles forms small slits or cuts which will eventually lead to deterioration. Should leakage occur, perform the following steps: 1. Using the supplied intradermal sealant and supplied 22-gauge syringe, remove the needle end of the syringe by twisting at the luer lock.
    [Show full text]
  • NEEDLE-FREE JET INJECTION BIBLIOGRAPHY, DEVICE & MANUFACTURER ROSTER, and PATENT LIST
    JET INJECTION Bibliography p. 1 of 79 Bruce G. Weniger file: Jetinject-Bib.doc & .pdf last update: 2004-Apr-06 NEEDLE-FREE JET INJECTION BIBLIOGRAPHY, DEVICE & MANUFACTURER ROSTER, and PATENT LIST last update: 2004-April-06 (Available at: http://www.cdc.gov/nip/dev/jetinject.htm#bibliography) New or updated entries added since website-posting of 2003-Dec-24: References: Carter2003, Haupt2003 Devices: GunA, EMS/RPM, EMS/MPM Patents: US 6063053, 6080130, 6156008, 6223786, 6302160 B2, 6447475 B1, 6474369 B2, 6500239 B2, 6610042 B2, 6613010 B2, 6613011 B2 Acknowledgements: Bibliography initiation, 1994-1995 – Lisa Lindsay, Emory Univ. Russian translations/summaries, 1999-2002 – Dr. Vitali Pool, CDC German translation, 2003 – Dr. Katrin Kohl, CDC Bibliographic retrievals and collection, 1998-2000 – Robyn Kaiser, Emory Univ. Update, April-May, 2002 – Christine Korhonen, Emory Univ. Barclay1962 – Joanne Penkalski, Academy of Medicine Cleveland/Northern Ohio Medical Association Béclard/Galante1866, Galante1866/1885 – Bernadette Molitor & Marie Peyraube, Bibliothèque Interuniversitaire de Médecine, Paris, France Linder1979 – Darin Zehrung, PATH, Seattle, Washington Schön1965 – Urda Guse, Zentrale Hochschulbibliothek, Lübeck, Germany Spiegel1994a – Philippe Stoeckel, Association pour l’Aide à la Médecine Préventive, Paris; Betty Dodet, Fondation Mérieux, Lyon, France Legend: ~R.200#MonDay: Reprint copy requested on date indicated. Double-indented items: Paper copy not yet received or not yet filed. *ID: Article on intradermal vaccination but NOT via needle-free injection device. Kindly please address any additions, updates, corrections, and suggestions to: Bruce G. Weniger, MD bgw2(-at-)cdc.gov Fax: [+1] 404-639-8834 JET INJECTION Bibliography p. 2 of 79 Bruce G. Weniger file: Jetinject-Bib.doc & .pdf last update: 2004-Apr-06 REFERENCES {Abb1981} Abb J, Deinhardt F, Eisenberg J.
    [Show full text]
  • Routes of Administration R UE of OUTES
    C HAPTER32 Routes of Administration R OUTES OF Shinya Shimizu A DMINISTRATION National Institute of Animal Health,Tsukuba, Japan increases successful treatment. Personnel using experi- General mental animals should be well trained in handling and restraint, should obtain authentication for responsible Mice are the most widely used animals for a range of use of experimental animals and attain a scientifically experiments including medical, chemical, pharmaco- high standard (ETS 123, 1986; Nebendahl, 2000). 527 logical, toxicological, biological, and genetic. The Further experience will lead to repeatable and reliable administration of test substances, such as chemical ele- results (see Chapter 31 on Handling and Restraint). P ments, compounds, drugs, antibodies, cells or other During administration mice should be protected ROCEDURES agents, to mice is one of the major methods for evalu- from pain, suffering, distress or lasting harm or at least ating their biological activity. pain and distress shall be kept to a minimum (ETS The route of administration is largely dependent on 123, 1986). Some injections (such as footpad injec- the property of the test substance and the objective of tion) are strongly discouraged and if required must be the experiment. All administration should be performed justified on a case by case basis (CCAC, 2002). with knowledge of the chemical and physical characteris- tics of the substance. All routes have both demerit and merit, such as the absorption, bioavailability and metab- olism of the substance. Consideration should be paid to Principles of the pH, viscosity, concentration, sterility, pyrogenicity, toxicity as well as the existence of hazardous substances. administration A knowledge of available methods and techniques of administration as well as knowledge of the deposition Handling and restraint and fate of the administered substance will help the scien- tist/investigator to select the most appropriate route for Good handling and restraint is the most important her/his purpose.
    [Show full text]
  • Comparison of the Effectiveness of Intradermal Injection of Lidocaine, Iontophoretic Delivery of Lidocaine, and Topical Emla
    Grand Valley State University ScholarWorks@GVSU Masters Theses Graduate Research and Creative Practice 1997 Comparison of the Effectiveness of Intradermal Injection of Lidocaine, Iontophoretic Delivery of Lidocaine, and Topical Emla Cream as Local Anesthetics for Venipuncture Carol Straight Grand Valley State University Follow this and additional works at: http://scholarworks.gvsu.edu/theses Part of the Nursing Commons Recommended Citation Straight, Carol, "Comparison of the Effectiveness of Intradermal Injection of Lidocaine, Iontophoretic Delivery of Lidocaine, and Topical Emla Cream as Local Anesthetics for Venipuncture" (1997). Masters Theses. 421. http://scholarworks.gvsu.edu/theses/421 This Thesis is brought to you for free and open access by the Graduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Masters Theses by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. COMPARISON OF THE EFFECTIVENESS OF INTRADERMAL INJECTION OF LIDOCAINE, lONTOPHORETIC DELIVERY OF LIDOCAINE, AND TOPICAL EMLA CREAM AS LOCAL ANESTHETICS FOR VENIPUNCTURE By Carol Straight A THESIS Submitted to Grand Valley State University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE IN NURSING Kirkhof School of Nursing 1997 Committee Members: Jean NageUcerk, R.N., Ph.D. Timothy Esser, M.D. Michelle Arthur, R.N., M S N. Terry Bauman, Pharm.D. ABSTRACT COMPARISON OF THE EFFECTIVENESS OF INTRADERMAL INJECTION OF LIDOCAINE, lONTOPHORETIC DELIVERY OF LIDOCAINE, AND TOPICAL EMLA CREAM AS LOCAL ANESTHETICS FOR VENIPUNCTURE By Carol Straight ' This study was undertaken to establish whether the administration of a local anesthetic, lidocaine, significantly reduces the pain of venipuncture in adults, to i g establish the degree of tolerability and effectiveness of each of three delivery methods for Lidocaine, and to identify recipient's preferences among the three pain-relieving measures.
    [Show full text]
  • Subcutaneous Injection Considerations for Needle Length and Gauge Selection*
    Subcutaneous injection considerations For needle length and gauge selection* Subcutaneous (SubQ) Location of injection Needle length Needle gauge Needle angle 12 months (infants) Anterolateral thigh, 1/2” – 5/8” 26 – 31 G upper outer tricep area, Pediatric 12 months to upper buttocks, 45º – 90º to adult 18 years abdomen (avoid 2” 5/32” – 1/2” 29 – 32 G radius around umilicus) (Diabetes Care) (Diabetes Care) > 18 years * Adapted from Fundamentals of Nursing: Human Health and Function. R. Craven, C. Hirnle, 4th ed. Lippincott Williams & Wilkins 2003. 30G 29G 28G 27G 26G 25G 24G 23G 22G 21G 20G 19G 18G ISO hub color standards for safety-engineered needles 50 45 40 35 30 25 Subcutaneous20 (SubQ) injection considerations: 15 10 4545° 9090° Injection procedure Outer aspect of the Outer aspect of the • Raise a fold of skin between upper thigh upper arm the thumb and forefinger, (not prefered site) and insert the needle at a 45º – 90º angle. • Pull back plunger slightly. If blood appears in syringe, remove needle, dispose properly and prepare a new injection.* * It is not necessary to aspirate for blood return when administering insulin or heparin. Abdomen—avoid Upper buttocks injecting within 2” around the umbilicus This information is being provided for convenience only and is not intended to replace clinical decision making. Each clinician is soley responsible for determinng the correct needle for each patient. bd.com BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2019 BD. All rights reserved.
    [Show full text]
  • Nursing Procedure for Initiating Subcutaneous Fluid Administration with Hylenex Recombinant
    Nursing Procedure for Initiating Subcutaneous Fluid Administration with hylenex recombinant PREP INSERT INFUSE Please see back cover for Indication and Important Safety Information and accompanying full Prescribing Information. These draft policies and procedures have been adapted from the Infusion Nurses Society (INS), the Oncology Nursing Society (ONS), and the hylenex recombinant (hyaluronidase human injection) prescribing information. It is the responsibility of the healthcare organization considering the use of this procedure to conduct an independent review and assessment to determine applicability and appropriateness of this document to their institution and to any particular clinical setting. Infusion therapies present risks; it is the responsibility of the healthcare organization to manage these risks, including the skills and competency validation of personnel. The healthcare organization that uses these guidelines should be aware that an annual review of organizational policies and procedures should continue to occur in accordance and compliance with regulatory and nonregulatory agencies. The Purpose of this Guide To outline nursing responsibilities in providing symptom control and/or fluid and electrolyte replacement by administering fluids subcutaneously. Policy Subcutaneous access is utilized to administer fluids via single injection or continuous infusion into the subcutaneous tissue. The fluid is absorbed through both adipose and connective tissue.1 hylenex recombinant is used for subcutaneous fluid administration, enabling enzymatically augmented subcutaneous infusion. In subcutaneous fluid administration, a catheter is placed in the subcutaneous tissue.1 Skilled and competent nurses knowledgeable in subcutaneous administration and the operation of electronic infusion devices may initiate and manage subcutaneous infusions.1 Some state and facility regulations allow this procedure to be performed by LVNs/LPNs.
    [Show full text]
  • Brief Note on Inactive Ingredients Approved by USFDA
    Brief note on Inactive Ingredients approved by USFDA FOR DIFFERENT DOSAGE FORMS WITH SPECIFIED ROUTE OF ADMINISTRATION Contents 1.0 Introduction………………..………………………………………………………………………………………………… 2.0 Inactive Ingredient Field Descriptions ….…………….....……………………………………………………… 3.0 Top Ten Inactive Ingredients……………….…………………………………………………………………………. a. List of Top 10 Inactive Ingredients (out of 3017) Approved by USFDA for specific dosage forms with specified route of administration-Pharmexcil Analysis (Table 1)….…………………….. 4.0 Top Ten Dosage Forms With Specific Route Of Administration And Number Of Inactive Ingredients……………………………………………………………………………………………………………………….. a. List indicating the number of inactive ingredients used in USFDA approved products for a specific route of administration and dosage form-Top 10-Pharmexcil Analysis (Table 2)…..….. b. Dosage form with specified route of administration vs. No. of Inactive ingredients approved by USFDA-Top 10- Pharmexcil Analysis (Figure 1)…...…………………………………………………………….. Figures: 1. Dosage form with specified route of administration vs. No. of Inactive ingredients approved by USFDA-Top 10- Pharmexcil Analysis Tables: 1. List of Top 10 Inactive Ingredients (out of 3017) Approved by USFDA for specific dosage forms with specified route of administration-Pharmexcil Analysis ………………………………..………………….. 2. List indicating the number of inactive ingredients used in USFDA approved products for a specific route of administration and dosage form-Top 10-Pharmexcil Analysis ……………..…..….. 3. List of Inactive ingredients approved by USFDA for specific dosage forms and route of administration – Pharmexcil Analysis………………………………………………………………………………………. 4. List indicating the number of inactive ingredients used in USFDA approved products for a specific route administration and dosage form – Pharmexcil Analysis ….………………………………….. 5. List of inactive ingredients for USFDA approved Drug Products………………………………………………... DISCLAIMER 1. The data should not be copied or transmitted to others in any means.
    [Show full text]